OBI Pharma, Inc. (TPEX:4174)
Taiwan · Delayed Price · Currency is TWD 26.00
+1.05 (4.21%)
Sep 8, 2026, 1:30 PM CST
OBI Pharma Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 52.2 | 58.58 | 62.68 | 41.55 | 4.71 | 18.77 |
Revenue Growth | -15.45% | -6.55% | 50.85% | 781.96% | -74.90% | -86.68% |
Gross Profit Gross Profit Growth | -79.67 | -77.53 | -76.27 | -73.5 | -40.14 | -25.59 |
Operating Income Operating Income Growth | -1,639 | -2,169 | -2,372 | -2,090 | -2,123 | -1,716 |
Net Income Net Income Growth | -1,526 | -2,053 | -2,310 | -1,046 | -1,614 | -1,531 |
Earnings Per Share EPS Growth | -11.60 | -15.61 | -19.78 | -9.14 | -14.53 | -15.39 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
New Anticancer Drug New Anticancer Drug Growth | 14.87 | 8.57 | 3.37 | 2.03 | 2 | 1.76 |
CDMO CDMO Growth | 40.83 | 69.27 | 87.41 | 68.83 | 62.5 | 34.81 |
Adjustments and Eliminations Adjustments and Eliminations Growth | -3.5 | -19.27 | -28.1 | -29.31 | -59.79 | -24.79 |
Total Total Growth | 52.2 | 58.58 | 62.68 | 41.55 | 4.71 | 18.77 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 496.96 | 1,186 | 3,131 | 2,782 | 4,773 | 2,654 |
Total Debt Total Debt Growth | 446.14 | 515.68 | 504.63 | 547.11 | 293.15 | 293.03 |
Net Cash (Debt) Net Cash Growth | 50.82 | 670.65 | 2,626 | 2,235 | 4,479 | 2,361 |
Net Cash Growth | -96.45% | -74.46% | 17.49% | -50.10% | 89.73% | -32.08% |
Net Cash Per Share Net Cash Per Share Growth | 0.39 | 5.10 | 22.48 | 19.52 | 40.33 | 23.73 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1,529 | -2,020 | -1,834 | -1,653 | -1,620 | -1,064 |
Capital Expenditures CapEx Growth | -19.43 | -43.87 | -113.24 | -101.93 | -254.65 | -241.33 |
Free Cash Flow Free Cash Flow Growth | -1,548 | -2,064 | -1,947 | -1,755 | -1,874 | -1,306 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -152.62% | -132.36% | -121.69% | -176.89% | - | -136.32% |
Operating Margin | -3139.94% | -3702.58% | -3783.67% | -5029.70% | -45059.69% | -9141.35% |
Pretax Margin | -3405.69% | -3857.41% | -3982.59% | -3070.00% | -40693.95% | -9281.13% |
Profit Margin | -2922.86% | -3504.61% | -3685.54% | -2518.65% | -34258.46% | -8154.10% |
FCF Margin | -2965.64% | -3523.70% | -3105.95% | -4223.71% | -39786.71% | -6956.13% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 106.36 | 106.36 | 106.36 | 106.36 | 106.36 |
PS Ratio | 62.89 | 121.22 | 245.51 | 382.92 | 3360.52 | 1208.19 |